Progress in the application of nanoparticles for the treatment of fungal infections: A review

References

• Abu Lila AS, Ishida T. 2017. Liposomal delivery systems: Design optimization and current applications. Biol Pharm Bull. 40(1):1–10. doi: 10.1248/bpb.b16-00624.
   PubMed Web of Science ®Google Scholar
• Agrawal Y, Petkar KC, Sawant KK. 2010. Development, evaluation and clinical studies of Acitretin loaded nanostructured lipid carriers for topical treatment of psoriasis. Int J Pharm. 401(1–2):93–102. doi: 10.1016/j.ijpharm.2010.09.007.
   PubMed Web of Science ®Google Scholar
• Ahmad S, Alfouzan W. 2021. Candida auris: Epidemiology, diagnosis, pathogenesis, antifungal susceptibility, and infection control measures to combat the spread of infections in healthcare facilities. Microorganisms. 9(4):807. doi: 10.3390/microorganisms9040807.
   PubMed Web of Science ®Google Scholar
• Akbarzadeh A, Rezaei-Sadabady R, Davaran S, Joo SW, Zarghami N, Hanifehpour Y, Samiei M, Kouhi M, Nejati-Koshki K. 2013. Liposome: Classification, preparation, and applications. Nanoscale Res Lett. 8(1):102. doi: 10.1186/1556-276X-8-102.
   PubMed Web of Science ®Google Scholar
• Akpan A, Morgan R. 2002. Oral candidiasis. Postgrad Med J. 78(922):455–459. doi: 10.1136/pmj.78.922.455.
   PubMed Web of Science ®Google Scholar
• Arastehfar A, Carvalho A, Houbraken J, Lombardi L, Garcia-Rubio R, Jenks JD, Rivero-Menendez O, Aljohani R, Jacobsen ID, Berman J, et al. 2021. Aspergillus fumigatus and aspergillosis: From basics to clinics. Stud Mycol. 100(1):100115. doi:10.1016/j.simyco.2021.100115.
   PubMedGoogle Scholar
• Arora S, Jain J, Rajwade JM, Paknikar KM. 2008. Cellular responses induced by silver nanoparticles: In vitro studies. Toxicol Lett. 179(2):93–100. doi: 10.1016/j.toxlet.2008.04.009.
   PubMed Web of Science ®Google Scholar
• Asharani PV, Low Kah Mun G, Hande MP, Valiyaveettil S. 2009. Cytotoxicity and genotoxicity of silver nanoparticles in human cells. Acs Nano. 3(2):279–290. doi: 10.1021/nn800596w.
   PubMed Web of Science ®Google Scholar
• Barnes PD, Marr KA. 2006. Aspergillosis: spectrum of disease, diagnosis, and treatment. Infect Dis Clin North Am. 20(3):545–561. doi: 10.1016/j.idc.2006.06.001.
   PubMed Web of Science ®Google Scholar
• Beloqui A, Solinís MA, Delgado A, Evora C, Pozo-Rodríguez AD, Rodríguez-Gascón A. 2013. Biodistribution of nanostructured lipid carriers (NLCs) after intravenous administration to rats: influence of technological factors. Eur J Pharm Biopharm. 84(2):309–314. doi: 10.1016/j.ejpb.2013.01.029.
   PubMed Web of Science ®Google Scholar
• Benjamin JT, Moore DJ, Bennett C, Van Der Meer R, Royce A, Loveland R, Wynn JL. 2018. Cutting edge: IL-1α and not IL-1β drives IL-1R1-dependent neonatal murine sepsis lethality. J Immunol. 201(10):2873–2878. doi: 10.4049/jimmunol.1801089.
   PubMed Web of Science ®Google Scholar
• Bhattacharya S, Sae-Tia S, Fries BC. 2020. Candidiasis and mechanisms of antifungal resistance. Antibiot (Basel). 9(6):312. doi: 10.3390/antibiotics9060312.
   PubMed Web of Science ®Google Scholar
• Billmyre RB, Applen Clancey S, Li LX, Doering TL, Heitman J. 2020. 5-fluorocytosine resistance is associated with hypermutation and alterations in capsule biosynthesis in Cryptococcus. Nat Commun. 11(1):127. doi: 10.1038/s41467-019-13890-z.
   PubMed Web of Science ®Google Scholar
• Bouz G, Doležal M. 2021. Advances in antifungal drug development: An up-to-date mini review. Pharmaceutic (Basel). 14(12):1312. doi: 10.3390/ph14121312.
   PubMedGoogle Scholar
• Brajtburg J, Powderly WG, Kobayashi GS, Medoff G. 1990. Amphotericin B: Current understanding of mechanisms of action. Antimicrob Agents Chemother. 34(2):183–188. doi: 10.1128/AAC.34.2.183.
   PubMed Web of Science ®Google Scholar
• Brown GD, Denning DW, Gow NA, Levitz SM, Netea MG, White TC. 2012. Hidden killers: Human fungal infections. Sci Transl Med. 4(165):165rv13. doi: 10.1126/scitranslmed.3004404.
   PubMed Web of Science ®Google Scholar
• Bruno M, Kersten S, Bain JM, Jaeger M, Rosati D, Kruppa MD, Lowman DW, Rice PJ, Graves B, Ma Z, et al. 2020. Transcriptional and functional insights into the host immune response against the emerging fungal pathogen Candida auris. Nat Microbiol. 5(12):1516–1531. doi: 10.1038/s41564-020-0780-3.
   PubMed Web of Science ®Google Scholar
• Buchanan KL, Murphy JW. 1998. What makes Cryptococcus neoformans a pathogen? Emerg Infect Dis. 4(1):71–83. doi: 10.3201/eid0401.980109.
   PubMed Web of Science ®Google Scholar
• Bueid A, Howard SJ, Moore CB, Richardson MD, Harrison E, Bowyer P, Denning DW. 2010. Azole antifungal resistance in Aspergillus fumigatus: 2008 and 2009. J Antimicrob Chemother. 65(10):2116–2118. doi: 10.1093/jac/dkq279.
   PubMed Web of Science ®Google Scholar
• Cadena J, Thompson GR 3rd, Patterson TF. 2021. Aspergillosis: Epidemiology, diagnosis, and treatment. Infect Dis Clin North Am. 35(2):415–434. doi: 10.1016/j.idc.2021.03.008.
   PubMed Web of Science ®Google Scholar
• Canturk Z. 2018. Evaluation of synergistic anticandidal and apoptotic effects of ferulic acid and caspofungin against Candida albicans. J Food Drug Anal. 26(1):439–443. doi: 10.1016/j.jfda.2016.12.014.
   PubMed Web of Science ®Google Scholar
• Chao A, Vazquez JA. 2021. Fungal infections of the gastrointestinal tract. Gastroenterol Clin North Am. 50(2):243–260. doi: 10.1016/j.gtc.2021.02.009.
   PubMed Web of Science ®Google Scholar
• Charpak-Amikam Y, Lapidus T, Isaacson B, Duev-Cohen A, Levinson T, Elbaz A, Levi-Schaffer F, Osherov N, Bachrach G, Hoyer LL, et al. 2022. Candida albicans evades NK cell elimination via binding of agglutinin-like sequence proteins to the checkpoint receptor TIGIT. Nat Commun. 13(1):2463. doi:10.1038/s41467-022-30087-z.
   PubMed Web of Science ®Google Scholar
• Chen G, Deng H, Song X, Lu M, Zhao L, Xia S, You G, Zhao J, Zhang Y, Dong A, et al. 2017. Reactive oxygen species-responsive polymeric nanoparticles for alleviating sepsis-induced acute liver injury in mice. Biomaterials. 144:30–41. doi: 10.1016/j.biomaterials.2017.08.008.
   PubMed Web of Science ®Google Scholar
• Cooke G, Watson C, Deckx L, Pirotta M, Smith J, Van Driel ML. 2022. Treatment for recurrent vulvovaginal candidiasis (thrush). Cochrane Database Syst Rev. 1(1):Cd009151. doi: 10.1002/14651858.CD009151.pub2.
   PubMedGoogle Scholar
• Cortés JCG, Curto M, Carvalho VSD, Pérez P, Ribas JC. 2019. The fungal cell wall as a target for the development of new antifungal therapies. Biotechnol Adv. 37(6):107352. doi: 10.1016/j.biotechadv.2019.02.008.
   PubMed Web of Science ®Google Scholar
• Cowen LE, Sanglard D, Howard SJ, Rogers PD, Perlin DS. 2014. Mechanisms of antifungal drug resistance. Cold Spring Harb Perspect Med. 5(7):a019752. doi: 10.1101/cshperspect.a019752.
   PubMed Web of Science ®Google Scholar
• Danek P, Kardosova M, Janeckova L, Karkoulia E, Vanickova K, Fabisik M, Lozano-Asencio C, Benoukraf T, Tirado-Magallanes R, Zhou Q, et al. 2020. β-Catenin-TCF/LEF signaling promotes steady-state and emergency granulopoiesis via G-CSF receptor upregulation. Blood. 136(22):2574–2587. doi: 10.1182/blood.2019004664.
   PubMed Web of Science ®Google Scholar
• Dewi IM, Janssen NA, Rosati D, Bruno M, Netea MG, Brüggemann RJ, Verweij PE, Van De Veerdonk FL. 2021. Invasive pulmonary aspergillosis associated with viral pneumonitis. Curr Opin Microbiol. 62:21–27. doi: 10.1016/j.mib.2021.04.006.
   PubMed Web of Science ®Google Scholar
• El-Ganiny AM, Kamel HA, Yossef NE, Mansour B, El-Baz AM. 2022. Repurposing pantoprazole and haloperidol as efflux pump inhibitors in azole resistant clinical Candida albicans and non-albicans isolates. Saudi Pharm J. 30(3):245–255. doi: 10.1016/j.jsps.2022.01.011.
   PubMed Web of Science ®Google Scholar
• El-Sheridy NA, Ramadan AA, Eid AA, El-Khordagui LK. 2019. Itraconazole lipid nanocapsules gel for dermatological applications: In vitro characteristics and treatment of induced cutaneous candidiasis. Colloids Surf B Biointerfaces. 181:623–631. doi: 10.1016/j.colsurfb.2019.05.057.
   PubMed Web of Science ®Google Scholar
• Fang JY, Tang KW, Yang SH, Alalaiwe A, Yang YC, Tseng CH, Yang SC. 2020. Synthetic naphthofuranquinone derivatives are effective in eliminating drug-resistant Candida albicans in hyphal, biofilm, and intracellular forms: An application for skin-infection treatment. Front Microbiol. 11:2053. doi: 10.3389/fmicb.2020.02053.
   PubMed Web of Science ®Google Scholar
• Feng X, Chen A, Zhang Y, Wang J, Shao L, Wei L. 2015. Central nervous system toxicity of metallic nanoparticles. Int J Nanomedicine. 10:4321–4340. doi: 10.2147/IJN.S78308.
   PubMed Web of Science ®Google Scholar
• Fraczek MG, Bromley M, Buied A, Moore CB, Rajendran R, Rautemaa R, Ramage G, Denning DW, Bowyer P. 2013. The cdr1B efflux transporter is associated with non-cyp51a-mediated itraconazole resistance in Aspergillus fumigatus. J Antimicrob Chemother. 68(7):1486–1496. doi: 10.1093/jac/dkt075.
   PubMed Web of Science ®Google Scholar
• Gao Q, Zhang J, Chen C, Chen M, Sun P, Du W, Zhang S, Liu Y, Zhang R, Bai M, et al. 2020. In situ mannosylated nanotrinity-mediated macrophage remodeling combats Candida albicans infection. Acs Nano. 14(4):3980–3990. doi: 10.1021/acsnano.9b07896.
   PubMed Web of Science ®Google Scholar
• Gonzalez-Jimenez I, Lucio J, Roldan A, Alcazar-Fuoli L, Mellado E. 2021. Are point mutations in HMG-CoA reductases (Hmg1 and Hmg2) a step towards azole resistance in Aspergillus fumigatus? Molecules. 26(19):5975. doi: 10.3390/molecules26195975.
   PubMed Web of Science ®Google Scholar
• Gonzalez CE, Rinaldi MG, Sugar AM. 2002. Zygomycosis. Infect Dis Clin North Am. 16(4):895–914. vi. doi: 10.1016/S0891-5520(02)00037-5.
   PubMed Web of Science ®Google Scholar
• González LM, Ruder WC, Mitchell AP, Messner WC, Leduc PR. 2015. Sudden motility reversal indicates sensing of magnetic field gradients in Magnetospirillum magneticum AMB-1 strain. ISME J. 9(6):1399–1409. doi: 10.1038/ismej.2014.224.
   PubMed Web of Science ®Google Scholar
• Goswami R, Dadhwal V, Tejaswi S, Datta K, Paul A, Haricharan RN, Banerjee U, Kochupillai NP. 2000. Species-specific prevalence of vaginal candidiasis among patients with diabetes mellitus and its relation to their glycaemic status. J Infect. 41(2):162–166. doi: 10.1053/jinf.2000.0723.
   PubMed Web of Science ®Google Scholar
• Groll AH, Rijnders BJA, Walsh TJ, Adler-Moore J, Lewis RE, Brüggemann RJM. 2019. Clinical pharmacokinetics, pharmacodynamics, safety and efficacy of liposomal amphotericin B. Clin Infect Dis. 68(Suppl 4):s260–s74. doi: 10.1093/cid/ciz076.
   PubMedGoogle Scholar
• Grover S, Sharma T, Singh Y, Kohli S, Manjunath P, Singh A, Semmler T, Wieler LH, Tedin K, Ehtesham NZ, et al. 2018. The PGRS domain of Mycobacterium tuberculosis PE_PGRS protein Rv0297 is involved in endoplasmic reticulum stress-mediated apoptosis through toll-like receptor 4. mBio. 9(3):e01017–18. doi: 10.1128/mBio.01017-18.
   PubMed Web of Science ®Google Scholar
• Gurunathan S, Han JW, Kwon DN, Kim JH. 2014. Enhanced antibacterial and anti-biofilm activities of silver nanoparticles against gram-negative and gram-positive bacteria. Nanoscale Res Lett. 9(1):373. doi: 10.1186/1556-276X-9-373.
   PubMedGoogle Scholar
• Hamill RJ. 2013. Amphotericin B formulations: A comparative review of efficacy and toxicity. Drugs. 73(9):919–934. doi: 10.1007/s40265-013-0069-4.
   PubMed Web of Science ®Google Scholar
• Hay RJ. 1994. Liposomal amphotericin B, AmBisome. J Infect. 28(1):35–43. doi: 10.1016/S0163-4453(94)95956-0.
   PubMedGoogle Scholar
• Hsin YH, Chen CF, Huang S, Shih TS, Lai PS, Chueh PJ. 2008. The apoptotic effect of nanosilver is mediated by a ROS- and JNK-dependent mechanism involving the mitochondrial pathway in NIH3T3 cells. Toxicol Lett. 179(3):130–139. doi: 10.1016/j.toxlet.2008.04.015.
   PubMed Web of Science ®Google Scholar
• Huang Y, Zang X, Yang C, Deng H, Ma X, Xie M, Zhou M, Song J, Xue X. 2022. Gene, virulence and related regulatory mechanisms in Cryptococcus gattii. Acta Biochim Biophys Sin (Shanghai). 54(5):593–603. doi: 10.3724/abbs.2022029.
   PubMed Web of Science ®Google Scholar
• Ingavale SS, Chang YC, Lee H, Mcclelland CM, Leong ML, Kwon-Chung KJ, Hull CM. 2008. Importance of mitochondria in survival of Cryptococcus neoformans under low oxygen conditions and tolerance to cobalt chloride. PLoS Pathog. 4(9):e1000155. doi: 10.1371/journal.ppat.1000155.
   PubMed Web of Science ®Google Scholar
• Iyer KR, Revie NM, Fu C, Robbins N, Cowen LE. 2021. Treatment strategies for cryptococcal infection: challenges, advances and future outlook. Nat Rev Microbiol. 19(7):454–466. doi: 10.1038/s41579-021-00511-0.
   PubMed Web of Science ®Google Scholar
• Jarvis JN, Lawrence DS, Meya DB, Kagimu E, Kasibante J, Mpoza E, Rutakingirwa MK, Ssebambulidde K, Tugume L, Rhein J, et al. 2022. Single-dose liposomal amphotericin B treatment for cryptococcal meningitis. N Engl J Med. 386(12):1109–1120. doi:10.1056/NEJMoa2111904.
   PubMed Web of Science ®Google Scholar
• Joshi KM, Shelar A, Kasabe U, Nikam LK, Pawar RA, Sangshetti J, Kale BB, Singh AV, Patil R, Chaskar MG. 2022. Biofilm inhibition in Candida albicans with biogenic hierarchical zinc-oxide nanoparticles. Biomater Adv. 134:112592. doi: 10.1016/j.msec.2021.112592.
   PubMedGoogle Scholar
• Jothiprakasam V, Sambantham M, Chinnathambi S, Vijayaboopathi S. 2017. Candida tropicalis biofilm inhibition by ZnO nanoparticles and EDTA. Arch Oral Biol. 73:21–24. doi: 10.1016/j.archoralbio.2016.09.003.
   PubMed Web of Science ®Google Scholar
• Kakkar V, Singh S, Singla D, Kaur IP. 2011. Exploring solid lipid nanoparticles to enhance the oral bioavailability of curcumin. Mol Nutr Food Res. 55(3):495–503. doi: 10.1002/mnfr.201000310.
   PubMed Web of Science ®Google Scholar
• Karunakaran G, Sudha KG, Ali S, Cho EB. 2023. Biosynthesis of nanoparticles from various biological sources and its biomedical applications. Molecules. 28(11):4527. doi: 10.3390/molecules28114527.
   PubMed Web of Science ®Google Scholar
• Katoh T. 2009. Guidelines for diagnosis and treatment of mucocutaneous candidiasis. Nihon Ishinkin Gakkai Zasshi. 50(4):207–212. doi: 10.3314/jjmm.50.207.
   PubMedGoogle Scholar
• Kawasaki ES, Player A. 2005. Nanotechnology, nanomedicine, and the development of new, effective therapies for cancer. Nanomed. 1(2):101–109. doi: 10.1016/j.nano.2005.03.002.
   PubMed Web of Science ®Google Scholar
• Kazakou N, Vyzantiadis TA, Gambeta A, Vasileiou E, Tsotridou E, Kotsos D, Giantsidi A, Saranti A, Palabougiouki M, Ioannidou M, et al. 2020. Invasive fungal infections in a pediatric hematology-oncology department: A 16-year retrospective study. Curr Med Mycol. 6(2):37–42. doi: 10.18502/cmm.6.2.2840.
   PubMedGoogle Scholar
• Khames A, Khaleel MA, El-Badawy MF, El-Nezhawy AOH. 2019. Natamycin solid lipid nanoparticles - sustained ocular delivery system of higher corneal penetration against deep fungal keratitis: Preparation and optimization. Int J Nanomedicine. 14:2515–2531. doi: 10.2147/IJN.S190502.
   PubMed Web of Science ®Google Scholar
• Khan S, Baboota S, Ali J, Khan S, Narang RS, Narang JK. 2015. Nanostructured lipid carriers: An emerging platform for improving oral bioavailability of lipophilic drugs. Int J Pharm Investig. 5(4):182–191. doi: 10.4103/2230-973X.167661.
   PubMed Web of Science ®Google Scholar
• Khan AR, Yang X, Fu M, Zhai G. 2018. Recent progress of drug nanoformulations targeting to brain. J Control Release. 291:37–64. doi: 10.1016/j.jconrel.2018.10.004.
   PubMed Web of Science ®Google Scholar
• Kim HJ, Kang SH, Choi SS, Kim ES. 2017. Redesign of antifungal polyene glycosylation: Engineered biosynthesis of disaccharide-modified NPP. Appl Microbiol Biotechnol. 101(12):5131–5137. doi: 10.1007/s00253-017-8303-8.
   PubMed Web of Science ®Google Scholar
• Kischkel B, Castilho PF, De Oliveira KM, Rezende PS, Bruschi ML, Svidzinski TI, Negri M. 2020. Silver nanoparticles stabilized with propolis show reduced toxicity and potential activity against fungal infections. Future Microbiol. 15(7):521–539. doi: 10.2217/fmb-2019-0173.
   PubMed Web of Science ®Google Scholar
• Kofla G, Ruhnke M. 2011. Pharmacology and metabolism of anidulafungin, caspofungin and micafungin in the treatment of invasive candidosis: Review of the literature. Eur J Med Res. 16(4):159–166. doi: 10.1186/2047-783X-16-4-159.
   PubMed Web of Science ®Google Scholar
• Kontoyiannis DP, Marr KA, Park BJ, Alexander BD, Anaissie EJ, Walsh TJ, Ito J, Andes DR, Baddley JW, Brown JM, et al. 2010. Prospective surveillance for invasive fungal infections in hematopoietic stem cell transplant recipients, 2001-2006: Overview of the transplant-associated infection surveillance Network (TRANSNET) database. Clin Infect Dis. 50(8):1091–1100. doi:10.1086/651263.
   PubMed Web of Science ®Google Scholar
• Koul B, Poonia AK, Yadav D, Jin JO. 2021. Microbe-mediated biosynthesis of nanoparticles: Applications and future prospects. Biomolecules. 11(6):886. doi: 10.3390/biom11060886.
   PubMed Web of Science ®Google Scholar
• Kumar S, Kaur P, Bernela M, Rani R, Thakur R. 2016. Ketoconazole encapsulated in chitosan-gellan gum nanocomplexes exhibits prolonged antifungal activity. Int J Biol Macromol. 93(Pt A):988–994. doi: 10.1016/j.ijbiomac.2016.09.042.
   PubMedGoogle Scholar
• Lee Y, Puumala E, Robbins N, Cowen LE. 2021. Antifungal drug resistance: Molecular mechanisms in Candida albicans and beyond. Chem Rev. 121(6):3390–3411. doi: 10.1021/acs.chemrev.0c00199.
   PubMed Web of Science ®Google Scholar
• Lesniak W, Bielinska AU, Sun K, Janczak KW, Shi X, Baker JR Jr., Balogh LP. 2005. Silver/dendrimer nanocomposites as biomarkers: fabrication, characterization, in vitro toxicity, and intracellular detection. Nano Lett. 5(11):2123–2130. doi: 10.1021/nl051077u.
   PubMed Web of Science ®Google Scholar
• Lewis JS 2nd, Wiederhold NP, Wickes BL, Patterson TF, Jorgensen JH. 2013. Rapid emergence of echinocandin resistance in Candida glabrata resulting in clinical and microbiologic failure. Antimicrob Agents Chemother. 57(9):4559–4561. doi: 10.1128/AAC.01144-13.
   PubMedGoogle Scholar
• Limper AH, Adenis A, Le T, Harrison TS. 2017. Fungal infections in HIV/AIDS. Lancet Infect Dis. 17(11):e334–e343. doi: 10.1016/S1473-3099(17)30303-1.
   PubMed Web of Science ®Google Scholar
• Li B, Pan L, Zhang H, Xie L, Wang X, Shou J, Qi Y, Yan X. 2021. Recent developments on using nanomaterials to combat Candida albicans. Front Chem. 9:813973. doi: 10.3389/fchem.2021.813973.
   PubMed Web of Science ®Google Scholar
• Liu JY, Wei B, Wang Y, Shi C, Li WJ, Zhao Y, Meng LN, Xiang MJ. 2020. The H741D mutation in Tac1p contributes to the upregulation of CDR1 and CDR2 expression in Candida albicans. Braz J Microbiol. 51(4):1553–1561. doi: 10.1007/s42770-020-00336-8.
   PubMed Web of Science ®Google Scholar
• Lytton-Jean AK, Langer R, Anderson DG. 2011. Five years of siRNA delivery: Spotlight on gold nanoparticles. Small. 7(14):1932–1937. doi: 10.1002/smll.201100761.
   PubMed Web of Science ®Google Scholar
• Machado M, Valerio M, Álvarez-Uría A, Olmedo M, Veintimilla C, Padilla B, De La Villa S, Guinea J, Escribano P, Ruiz-Serrano MJ, et al. 2021. Invasive pulmonary aspergillosis in the COVID-19 era: An expected new entity. Mycoses. 64(2):132–143. doi:10.1111/myc.13213.
   PubMed Web of Science ®Google Scholar
• Maheen S, Younis H, Khan HU, Salman Shafqat S, Ali S, Rehman AU, Ilyas S, Zafar MN, Shafqat SR, Kalam A, et al. 2022. Enhanced antifungal and wound healing efficacy of statistically optimized, physicochemically evaluated econazole-triamcinolone loaded silica nanoparticles. Front Chem. 10:836678. doi: 10.3389/fchem.2022.836678.
   PubMed Web of Science ®Google Scholar
• Meis JF, Chowdhary A, Rhodes JL, Fisher MC, Verweij PE. 2016. Clinical implications of globally emerging azole resistance in Aspergillus fumigatus. Philos Trans R Soc Lond B Biol Sci. 371(1709):20150460. doi: 10.1098/rstb.2015.0460.
   PubMed Web of Science ®Google Scholar
• Moazeni M, Kelidari HR, Saeedi M, Morteza-Semnani K, Nabili M, Gohar AA, Akbari J, Lotfali E, Nokhodchi A. 2016. Time to overcome fluconazole resistant Candida isolates: Solid lipid nanoparticles as a novel antifungal drug delivery system. Colloids Surf B Biointerfaces. 142:400–407. doi: 10.1016/j.colsurfb.2016.03.013.
   PubMed Web of Science ®Google Scholar
• Mohammadi G, Shakeri A, Fattahi A, Mohammadi P, Mikaeili A, Aliabadi A, Adibkia K. 2017. Preparation, physicochemical characterization and anti-fungal evaluation of nystatin-loaded PLGA-glucosamine nanoparticles. Pharm Res. 34(2):301–309. doi: 10.1007/s11095-016-2062-6.
   PubMed Web of Science ®Google Scholar
• Mondal D, Alvar J, Hasnain MG, Hossain MS, Ghosh D, Huda MM, Nabi SG, Sundar S, Matlashewski G, Arana B. 2014. Efficacy and safety of single-dose liposomal amphotericin B for visceral leishmaniasis in a rural public hospital in Bangladesh: A feasibility study. Lancet Glob Health. 2(1):e51–7. doi: 10.1016/S2214-109X(13)70118-9.
   PubMed Web of Science ®Google Scholar
• Mosser DM. 2003. The many faces of macrophage activation. J Leukoc Biol. 73(2):209–212. doi: 10.1189/jlb.0602325.
   PubMed Web of Science ®Google Scholar
• Mu H, Holm R. 2018. Solid lipid nanocarriers in drug delivery: Characterization and design. Expert Opin Drug Deliv. 15(8):717–785. doi: 10.1080/17425247.2018.1504018.
   PubMed Web of Science ®Google Scholar
• Nisini R, Poerio N, Mariotti S, De Santis F, Fraziano M. 2018. The multirole of liposomes in therapy and prevention of infectious diseases. Front Immunol. 9:155. doi: 10.3389/fimmu.2018.00155.
   PubMed Web of Science ®Google Scholar
• Ostrowsky B, Greenko J, Adams E, Quinn M, O’brien B, Chaturvedi V, Berkow E, Vallabhaneni S, Forsberg K, Chaturvedi S, et al. 2020. Candida auris isolates resistant to three classes of antifungal medications - New York, 2019. MMWR Morb Mortal Wkly Rep. 69(1):6–9. doi: 10.15585/mmwr.mm6901a2.
   PubMed Web of Science ®Google Scholar
• Panácek A, Kolár M, Vecerová R, Prucek R, Soukupová J, Krystof V, Hamal P, Zboril R, Kvítek L. 2009. Antifungal activity of silver nanoparticles against Candida spp. Biomaterials. 30(31):6333–6340. doi: 10.1016/j.biomaterials.2009.07.065.
   PubMed Web of Science ®Google Scholar
• Panwar R, Pemmaraju SC, Sharma AK, Pruthi V. 2016. Efficacy of ferulic acid encapsulated chitosan nanoparticles against Candida albicans biofilm. Microb Pathog. 95:21–31. doi: 10.1016/j.micpath.2016.02.007.
   PubMed Web of Science ®Google Scholar
• Pappas PG, Lionakis MS, Arendrup MC, Ostrosky-Zeichner L, Kullberg BJ. 2018. Invasive candidiasis. Nat Rev Dis Primers. 4(1):18026. doi: 10.1038/nrdp.2018.26.
   PubMed Web of Science ®Google Scholar
• Paraguay-Delgado F, Hermida-Montero LA, Morales-Mendoza JE, Durán-Barradas Z, Mtz-Enriquez AI, Pariona N. 2022. Photocatalytic properties of cu-containing ZnO nanoparticles and their antifungal activity against agriculture-pathogenic fungus. RSC Adv. 12(16):9898–9908. doi: 10.1039/D2RA00863G.
   PubMed Web of Science ®Google Scholar
• Pardeike J, Weber S, Zarfl HP, Pagitz M, Zimmer A. 2016. Itraconazole-loaded nanostructured lipid carriers (NLC) for pulmonary treatment of aspergillosis in falcons. Eur J Pharm Biopharm. 108:269–276. doi: 10.1016/j.ejpb.2016.07.018.
   PubMed Web of Science ®Google Scholar
• Park JH, Saravanakumar G, Kim K, Kwon IC. 2010. Targeted delivery of low molecular drugs using chitosan and its derivatives. Adv Drug Deliv Rev. 62(1):28–41. doi: 10.1016/j.addr.2009.10.003.
   PubMed Web of Science ®Google Scholar
• Paulo CS, Vidal M, Ferreira LS. 2010. Antifungal nanoparticles and surfaces. Biomacromolecules. 11(10):2810–2817. doi: 10.1021/bm100893r.
   PubMed Web of Science ®Google Scholar
• Pfaller MA, Diekema DJ. 2007. Epidemiology of invasive candidiasis: a persistent public health problem. Clin Microbiol Rev. 20(1):133–163. doi: 10.1128/CMR.00029-06.
   PubMed Web of Science ®Google Scholar
• Pfaller MA, Diekema DJ, Turnidge JD, Castanheira M, Jones RN. 2019. Twenty years of the SENTRY antifungal surveillance program: Results for Candida species from 1997-2016. Open Forum Infect Dis. 6(Suppl 1):s79–s94. doi: 10.1093/ofid/ofy358.
   PubMedGoogle Scholar
• Pourhoseini S, Enos RT, Murphy AE, Cai B, Lead JR. 2021. Characterization, bio-uptake and toxicity of polymer-coated silver nanoparticles and their interaction with human peripheral blood mononuclear cells. Beilstein J Nanotechnol. 12:282–294. doi: 10.3762/bjnano.12.23.
   PubMed Web of Science ®Google Scholar
• Queiroz-Telles F, Fahal AH, Falci DR, Caceres DH, Chiller T, Pasqualotto AC. 2017. Neglected endemic mycoses. Lancet Infect Dis. 17(11):e367–e377. doi: 10.1016/S1473-3099(17)30306-7.
   PubMed Web of Science ®Google Scholar
• Rajan R, Huo P, Chandran K, Manickam Dakshinamoorthi B, Yun SI, Liu B. 2022. A review on the toxicity of silver nanoparticles against different biosystems. Chemosphere. 292:133397. doi: 10.1016/j.chemosphere.2021.133397.
   PubMed Web of Science ®Google Scholar
• Resendiz Sharpe A, Lagrou K, Meis JF, Chowdhary A, Lockhart SR, Verweij PE. 2018. Triazole resistance surveillance in Aspergillus fumigatus. Med Mycol. 56(suppl_1):83–92. doi: 10.1093/mmy/myx144.
   PubMedGoogle Scholar
• Roca-Barcelo A, Douglas P, Fecht D, Sterrantino AF, Williams B, Blangiardo M, Gulliver J, Hayes ET, Hansell AL. 2020. Risk of respiratory hospital admission associated with modelled concentrations of aspergillus fumigatus from composting facilities in England. Environ Res. 183:108949. doi: 10.1016/j.envres.2019.108949.
   PubMed Web of Science ®Google Scholar
• Roca FJ, Whitworth LJ, Redmond S, Jones AA, Ramakrishnan L. 2019. TNF induces pathogenic programmed macrophage necrosis in tuberculosis through a mitochondrial-lysosomal-endoplasmic reticulum circuit. Cell. 178(6):1344–61.e11. doi: 10.1016/j.cell.2019.08.004.
   PubMed Web of Science ®Google Scholar
• Roden MM, Zaoutis TE, Buchanan WL, Knudsen TA, Sarkisova TA, Schaufele RL, Sein M, Sein T, Chiou CC, Chu JH, et al. 2005. Epidemiology and outcome of zygomycosis: A review of 929 reported cases. Clin Infect Dis. 41(5):634–653. doi:10.1086/432579.
   PubMed Web of Science ®Google Scholar
• Rosi NL, Mirkin CA. 2005. Nanostructures in biodiagnostics. Chem Rev. 105(4):1547–1562. doi: 10.1021/cr030067f.
   PubMed Web of Science ®Google Scholar
• Rouzaud C, Hay R, Chosidow O, Dupin N, Puel A, Lortholary O, Lanternier F. 2015. Severe dermatophytosis and acquired or innate immunodeficiency: A review. J Fungi (Basel). 2(1):4. doi: 10.3390/jof2010004.
   PubMedGoogle Scholar
• Russell DG, Huang L, Vanderven BC. 2019. Immunometabolism at the interface between macrophages and pathogens. Nat Rev Immunol. 19(5):291–304. doi: 10.1038/s41577-019-0124-9.
   PubMed Web of Science ®Google Scholar
• Saldanha CA, Garcia MP, Iocca DC, Rebelo LG, Souza AC, Bocca AL, Almeida Santos Mde F, Morais PC, Azevedo RB, Vinetz JM. 2016. Antifungal activity of amphotericin B conjugated to nanosized magnetite in the treatment of paracoccidioidomycosis. PLoS Negl Trop Dis. 10(6):e0004754. doi: 10.1371/journal.pntd.0004754.
   PubMed Web of Science ®Google Scholar
• Sandhu SK, Kumar S, Raut J, Singh M, Kaur S, Sharma G, Roldan TL, Trehan S, Holloway J, Wahler G, et al. 2021. Systematic development and characterization of novel, high drug-loaded, photostable, curcumin solid lipid nanoparticle hydrogel for wound healing. Antioxid (Basel). 10(5):725. doi:10.3390/antiox10050725.
   PubMedGoogle Scholar
• Satoh K, Makimura K, Hasumi Y, Nishiyama Y, Uchida K, Yamaguchi H. 2009. Candida auris sp. nov., a novel ascomycetous yeast isolated from the external ear canal of an inpatient in a Japanese hospital. Microbiol Immunol. 53(1):41–44. doi: 10.1111/j.1348-0421.2008.00083.x.
   PubMed Web of Science ®Google Scholar
• Saxena S, Khan JA, Ghosh PC. 1998. Toxicity and therapeutic efficacy of amphotericin B delivered through cholesterol hemisuccinate vesicles in the treatment of experimental murine aspergillosis. J Antimicrob Chemother. 42(5):635–642. doi: 10.1093/jac/42.5.635.
   PubMed Web of Science ®Google Scholar
• Seagle EE, Williams SL, Chiller TM. 2021. Recent trends in the epidemiology of fungal infections. Infect Dis Clin North Am. 35(2):237–260. doi: 10.1016/j.idc.2021.03.001.
   PubMed Web of Science ®Google Scholar
• Seider K, Heyken A, Lüttich A, Miramón P, Hube B. 2010. Interaction of pathogenic yeasts with phagocytes: Survival, persistence and escape. Curr Opin Microbiol. 13(4):392–400. doi: 10.1016/j.mib.2010.05.001.
   PubMed Web of Science ®Google Scholar
• Seyedmousavi S, Mouton JW, Melchers WJ, Brüggemann RJ, Verweij PE. 2014. The role of azoles in the management of azole-resistant aspergillosis: From the bench to the bedside. Drug Resist Updat. 17(3):37–50. doi: 10.1016/j.drup.2014.06.001.
   PubMed Web of Science ®Google Scholar
• Shapiro RS, Robbins N, Cowen LE. 2011. Regulatory circuitry governing fungal development, drug resistance, and disease. Microbiol Mol Biol Rev. 75(2):213–267. doi: 10.1128/MMBR.00045-10.
   PubMed Web of Science ®Google Scholar
• Simitsopoulou M, Peshkova P, Tasina E, Katragkou A, Kyrpitzi D, Velegraki A, Walsh TJ, Roilides E. 2013. Species-specific and drug-specific differences in susceptibility of Candida biofilms to echinocandins: Characterization of less common bloodstream isolates. Antimicrob Agents Chemother. 57(6):2562–2570. doi: 10.1128/AAC.02541-12.
   PubMed Web of Science ®Google Scholar
• Snelders E, Huis I‘, Veld RA, Rijs AJ, Kema GH, Melchers WJ, Verweij PE. 2009. Possible environmental origin of resistance of Aspergillus fumigatus to medical triazoles. Appl Environ Microbiol. 75(12):4053–4057. doi: 10.1128/AEM.00231-09.
   PubMed Web of Science ®Google Scholar
• Soliman GM. 2017. Nanoparticles as safe and effective delivery systems of antifungal agents: Achievements and challenges. Int J Pharm. 523(1):15–32. doi: 10.1016/j.ijpharm.2017.03.019.
   PubMed Web of Science ®Google Scholar
• Souza JGS, Costa RC, Sampaio AA, Abdo VL, Nagay BE, Castro N, Retamal-Valdes B, Shibli JA, Feres M, VaR B, et al. 2022. Cross-kingdom microbial interactions in dental implant-related infections: Is Candida albicans a new villain? iScience. 25(4):103994. doi: 10.1016/j.isci.2022.103994.
   PubMed Web of Science ®Google Scholar
• Stott KE, Loyse A, Jarvis JN, Alufandika M, Harrison TS, Mwandumba HC, Day JN, Lalloo DG, Bicanic T, Perfect JR, et al. 2021. Cryptococcal meningoencephalitis: Time for action. Lancet Infect Dis. 21(9):e259–e271. doi: 10.1016/S1473-3099(20)30771-4.
   PubMed Web of Science ®Google Scholar
• Tang F, Li L, Chen D. 2012. Mesoporous silica nanoparticles: Synthesis, biocompatibility and drug delivery. Adv Mater. 24(12):1504–1534. doi: 10.1002/adma.201104763.
   PubMed Web of Science ®Google Scholar
• Thomas CF, Limper AH. 2004. Pneumocystis pneumonia. N Engl J Med. 350(24):2487–2498. doi: 10.1056/NEJMra032588.
   PubMed Web of Science ®Google Scholar
• Thomas CF, Limper AH. 2007. Current insights into the biology and pathogenesis of pneumocystis pneumonia. Nat Rev Microbiol. 5(4):298–308. doi: 10.1038/nrmicro1621.
   PubMed Web of Science ®Google Scholar
• Torella JP, Chait R, Kishony R, Bourne PE. 2010. Optimal drug synergy in antimicrobial treatments. PLoS Comput Biol. 6(6):e1000796. doi: 10.1371/journal.pcbi.1000796.
   PubMed Web of Science ®Google Scholar
• Vaghasiya H, Kumar A, Sawant K. 2013. Development of solid lipid nanoparticles based controlled release system for topical delivery of terbinafine hydrochloride. Eur J Pharm Sci. 49(2):311–322. doi: 10.1016/j.ejps.2013.03.013.
   PubMed Web of Science ®Google Scholar
• Van Leth F, Schultsz C. 2023. Unbiased antimicrobial resistance prevalence estimates through population-based surveillance. Clin Microbiol Infect. 29(4):429–433. doi: 10.1016/j.cmi.2022.05.006.
   PubMed Web of Science ®Google Scholar
• Varela-Fernández R, García-Otero X, Díaz-Tomé V, Regueiro U, López-López M, González-Barcia M, Isabel Lema M, Javier Otero-Espinar F. 2022. Lactoferrin-loaded nanostructured lipid carriers (NLCs) as a new formulation for optimized ocular drug delivery. Eur J Pharm Biopharm. 172:144–156. doi: 10.1016/j.ejpb.2022.02.010.
   PubMed Web of Science ®Google Scholar
• Verweij PE, Mellado E, Melchers WJ. 2007. Multiple-triazole-resistant aspergillosis. N Engl J Med. 356(14):1481–1483. doi: 10.1056/NEJMc061720.
   PubMed Web of Science ®Google Scholar
• Verweij PE, Snelders E, Kema GH, Mellado E, Melchers WJ. 2009. Azole resistance in Aspergillus fumigatus: A side-effect of environmental fungicide use? Lancet Infect Dis. 9(12):789–795. doi: 10.1016/S1473-3099(09)70265-8.
   PubMed Web of Science ®Google Scholar
• Walker L, Sood P, Lenardon MD, Milne G, Olson J, Jensen G, Wolf J, Casadevall A, Adler-Moore J, Gow Na R, et al. 2018. The viscoelastic properties of the fungal cell wall allow traffic of ambisome as intact liposome vesicles. mBio. 9(1):e02383–17. doi: 10.1128/mBio.02383-17.
   PubMed Web of Science ®Google Scholar
• Weldick PJ, Wang A, Halbus AF, Paunov VN. 2022. Emerging nanotechnologies for targeting antimicrobial resistance. Nanoscale. 14(11):4018–4041. doi: 10.1039/D1NR08157H.
   PubMed Web of Science ®Google Scholar
• Wiederhold NP, Kontoyiannis DP, Prince RA, Lewis RE. 2005. Attenuation of the activity of caspofungin at high concentrations against candida albicans: Possible role of cell wall integrity and calcineurin pathways. Antimicrob Agents Chemother. 49(12):5146–5148. doi: 10.1128/AAC.49.12.5146-5148.2005.
   PubMed Web of Science ®Google Scholar
• Wiederhold NP, Verweij PE. 2020. Aspergillus fumigatus and pan-azole resistance: Who should be concerned? Curr Opin Infect Dis. 33(4):290–297. doi: 10.1097/QCO.0000000000000662.
   PubMed Web of Science ®Google Scholar
• Wisplinghoff H, Bischoff T, Tallent SM, Seifert H, Wenzel RP, Edmond MB. 2004. Nosocomial bloodstream infections in US hospitals: analysis of 24,179 cases from a prospective nationwide surveillance study. Clin Infect Dis. 39(3):309–317. doi: 10.1086/421946.
   PubMed Web of Science ®Google Scholar
• Wong TY, Loo YS, Veettil SK, Wong PS, Divya G, Ching SM, Menon RK. 2020. Efficacy and safety of posaconazole for the prevention of invasive fungal infections in immunocompromised patients: A systematic review with meta-analysis and trial sequential analysis. Sci Rep. 10(1):14575. doi: 10.1038/s41598-020-71571-0.
   PubMed Web of Science ®Google Scholar
• Xiao Z, Wang Q, Zhu F, An Y. 2019. Epidemiology, species distribution, antifungal susceptibility and mortality risk factors of candidemia among critically ill patients: A retrospective study from 2011 to 2017 in a teaching hospital in China. Antimicrob Resist Infect Control. 8(1):89. doi: 10.1186/s13756-019-0534-2.
   PubMed Web of Science ®Google Scholar
• Zhao Y, Liu S, Shi Z, Zhu H, Li M, Yu Q. 2022. Pathogen infection-responsive nanoplatform targeting macrophage endoplasmic reticulum for treating life-threatening systemic infection. Nano Res. 15(7):6243–6255. doi: 10.1007/s12274-022-4211-z.
   PubMed Web of Science ®Google Scholar
• Zheng X, Huang X, Luo J, Li J, Li W, Liu Q, Niu T, Wang X, Zhou J, Zhang X, et al. 2018. Effectiveness and tolerability of micafungin in Chinese patients with invasive fungal infections: a retrospective, multicenter study. Adv Ther. 35(9):1400–1410. doi:10.1007/s12325-018-0762-5.
   PubMed Web of Science ®Google Scholar
• Zhi K, Raji B, Nookala AR, Khan MM, Nguyen XH, Sakshi S, Pourmotabbed T, Yallapu MM, Kochat H, Tadrous E, et al. 2021. PLGA nanoparticle-based formulations to cross the blood–brain barrier for drug delivery: From R&D to cGMP. Pharmaceutics. 13(4):500. doi: 10.3390/pharmaceutics13040500.
   PubMed Web of Science ®Google Scholar
• Zielińska A, Carreiró F, Oliveira AM, Neves A, Pires B, Venkatesh DN, Durazzo A, Lucarini M, Eder P, Silva AM, et al. 2020. Polymeric nanoparticles: Production, characterization, toxicology and ecotoxicology. Molecules. 25(16):3731. doi: 10.3390/molecules25163731.
   PubMed Web of Science ®Google Scholar
• Zuo XS, Liu Y, Cai X, Zhan L, Hu K. 2021. Association of different Candida species with catheter-related candidemia, and the potential antifungal treatments against their adhesion properties and biofilm-forming capabilities. J Clin Lab Anal. 35(4):e23738. doi: 10.1002/jcla.23738.
   PubMed Web of Science ®Google Scholar